Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients infected with Clonorchis sinensis
- Conditions
- ClonorchiasisInfections and Infestations
- Registration Number
- ISRCTN55086560
- Lead Sponsor
- The National Institute of Parasitic Diseases (China)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 120
Current inclusion criteria as of 14/08/2012:
Eligible patients are residents of Hunan province aged 15 to 65 years who have Clonorchis sinensis infections, both sexes.
Previous inclusion criteria until 14/08/2012:
Eligible patients are residents of Guangdong province aged 2 years and above who had Clonorchis sinensis infections, both sexes
1. Pregnant or lactating women
2. Presence of any abnormal medical condition, such as heart disease, high blood pressure, severe malnutrition, severe liver and kidney disease, psychiatric and neurologic disorders
3. Use of praziquantel , tribendimidine, albendazole and mebendazole or any anthelminthic treatment within the past month
4. Enrolled in any other clinical investigation during the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Egg reduction rate (ERR) and cure rate (CR), measured using the Kato-Katz stool examination method<br>2. Adverse reactions, measured using a standardised questionnaire. The intensity of adverse events was graded as mild, moderate, severe and serious<br><br>Assessed at 4 weeks after treatment
- Secondary Outcome Measures
Name Time Method All the participants who are to receive the tribendimidine treatment will accept checks of blood, urine, electrocardiogram, liver function and kidney function before and after the treatment. The abnormal indexes will be supervised and recorded.